Nov 14 (Reuters) - Shares of Hims & Hers Health HIMS.N slumped 15% on Thursday after Amazon.com AMZN.O launched a rival service that offers upfront pricing for telehealth visits.
Amazon said it is introducing low, upfront pricing for a clinical visit, treatment plan, and free medication delivery for Prime members for a range of common health, beauty and lifestyle concerns.
Similarly, Hims & Hers connects patients to licensed healthcare professionals through its online platform and offers treatments for a range of conditions.
"Amazon's rollout appears to offer a similar idea of convenience at what appears to be a lower price point across the board. We don't know how successful it will be, but also note that this is a serious competitive threat being introduced to the market," said Leerink Partners analyst Michael Cherny.
Customers can see both the prices for their telehealth consultation and medication from Amazon Pharmacy before moving forward with care, Amazon said.
Given Amazon is offering much more compelling prices than Hims & Hers on most treatments, we do think this is a threat to Hims' core offering, said Citi analyst Daniel Grosslight.
Shares of Hims & Hers have more than doubled this year after the company began offering compounded GLP-1 weight-loss injections, such as Novo Nordisk's NOVOb.CO Wegovy.
Amazon's move makes Hims & Hers' strategy to personalize treatment via compounding ever-more important, Grosslight added.
(Reporting by Sneha S K in Bengaluru; Editing by Shailesh Kuber)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。